SPONSORED CONTENT
Q1 2026 started rougher than predicted for 340B programs. Ceiling prices compressed. Penny pricing disappeared on drugs that used to be your biggest savings. And an entire drug category that looked like a growth engine 12 months ago went dark almost
…



